Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Non-Current Liabilities (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Total Non-Current Liabilities for 13 consecutive years, with $346.6 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 192.28% to $346.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $346.6 million through Dec 2025, up 192.28% year-over-year, with the annual reading at $346.6 million for FY2025, 192.28% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $346.6 million at Madrigal Pharmaceuticals, roughly flat from $345.3 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $346.6 million in Q4 2025, with the low at $283000.0 in Q1 2022.
  • Average Total Non-Current Liabilities over 5 years is $98.5 million, with a median of $107.6 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities dropped 26.87% in 2022, then skyrocketed 29569.61% in 2023.
  • Over 5 years, Total Non-Current Liabilities stood at $387000.0 in 2021, then soared by 12636.18% to $49.3 million in 2022, then soared by 136.7% to $116.7 million in 2023, then rose by 1.65% to $118.6 million in 2024, then surged by 192.28% to $346.6 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $346.6 million, $345.3 million, and $122.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.